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Expression of Toll-Like Receptor 4 Contributes to Corneal
Inflammation in Experimental Dry Eye Disease
Hyun Soo Lee,1,2 Takaaki Hattori,1 Eun Young Park,1 William Stevenson,1 Sunil K. Chauhan,1
and Reza Dana1
PURPOSE. To investigate the corneal expression of toll-like
receptor (TLR) 4 and determine its contribution to the
immunopathogenesis of dry eye disease (DED).
METHODS. Seven to 8-week-old female C57BL/6 mice were
housed in a controlled environment chamber and administered
scopolamine to induce experimental DED. Mice received
intravenous TLR4 inhibitor (Eritoran) to block systemic TLR4-
mediated activity. The expression of TLR4 by the corneal
epithelium and stroma was evaluated using real-time polymer-
ase chain reaction and flow cytometry. Corneal fluorescein
staining (CFS) was performed to evaluate clinical disease
severity. The corneal expression of proinflammatory cytokines
(IL-1b, IL-6, TNF, and CCL2), corneal infiltration of CD11bþ
antigen-presenting cells, and lymph node frequency of mature
MHC-IIhi CD11bþ cells were assessed.
RESULTS. The epithelial cells of normal corneas expressed TLR4
intracellularly; however, DED significantly increased the cell
surface expression of TLR4. Similarly, flow cytometric analysis
of stromal cells revealed a significant increase in the expression
of TLR4 proteins by DED-induced corneas as compared with
normal corneas. DED increased the mRNA expression of TLR4
in corneal stromal cells, but not epithelial cells. TLR4 inhibition
decreased the severity of CFS and significantly reduced the
mRNA expression of IL-1b, IL-6, and TNF. Furthermore, TLR4
inhibition significantly reduced the corneal infiltration of
CD11bþ cells and the lymph node frequency of MHC-IIhi
CD11bþ cells.
CONCLUSIONS. These results suggest that DED increases the
corneal expression of TLR4 and that TLR4 participates in the
inflammatory response to ocular surface desiccating stress.
(Invest Ophthalmol Vis Sci. 2012;53:5632–5640) DOI:
10.1167/iovs.12-9547
Dry eye disease (DED), one of the most common ocularcomplaints, is an immunoinflammatory disorder of the
ocular surface; however, the immunopathogenesis of DED has
not yet been fully described.1,2 The 2007 Dry Eye WorkShop
concluded that tear film instability and hyperosmolarity induce
ocular surface inflammation.3 Recent studies have demonstrat-
ed that corneal epithelial cells respond to hyperosmolar stress
by producing proinflammatory cytokines, chemokines, and
matrix metalloproteinases (MMPs).4,5 Furthermore, hyperos-
molar stress and proinflammatory cytokines such as interferon
(IFN)-c promote epithelial cell apoptosis.5–8
Toll-like receptors (TLRs) are pattern recognition receptors
of the innate immune system that recognize highly conserved
microbial structures and products.9,10 To date, 12 murine
TLRs have been identified, and TLRs are expressed by a variety
of cell types, including epithelial cells, dendritic cells,
macrophages, and lymphocytes.10–13 TLR stimulation leads
to the activation of nuclear factor-kappaB (NF-jB) that
upregulates the production of proinflammatory cytokines
and antimicrobial proteins.10,14 The NF-jB signaling pathway
is important for the induction of innate and adaptive immune
responses.10,14
TLR4 recognizes the Gram-negative bacterial cell wall
component lipopolysaccharide (LPS) in association with cofac-
tors such as CD14, LPS-binding protein (LBP), and myeloid
differentiation factor-2 (MD-2).15,16 It has also been suggested
that TLR4 is a receptor for endogenous ligands associated with
noninfectious diseases such as myocardial ischemia-reperfusion
injury and central nervous system autoimmune disease.17,18 We
hypothesized that DED-induced corneal inflammation and
injury may lead to the production of endogenous TLR4 ligands
that activate the immune system. Therefore, we investigated the
corneal expression of TLR4 and sought to determine the
expression pattern of TLR4 in DED.
MATERIALS AND METHODS
Animals
Seven to 8-week-old female C57BL/6 mice (Charles River Laboratories,
Wilmington, MA) were used for these experiments. The experimental
protocol was approved by the Institutional Animal Care and Use
Committee, and all animals were managed according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Dry Eye Model
DED was induced by placing mice in a controlled environment
chamber (CEC) and administering scopolamine (Sigma–Aldrich, St.
Louis, MO) to maximize ocular surface dryness, as previously
described.19,20 Mice placed in the CEC were exposed to a relative
humidity < 25%, temperature of 20 to 228C, and airflow of 15 L/min,
24 hours per day. Scopolamine hydrobromide (0.5 mg/0.2 mL) was
injected subcutaneously in the dorsal skin of mice three times per day.
Age- and sex-matched mice placed in the standard vivarium served as
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normal controls. Mice were euthanized on day 7 or day 9 for cellular
and molecular analysis.
Corneal Fluorescein Staining
To evaluate the effects of desiccating stress on the ocular surface,
corneal fluorescein staining (CFS) was performed at baseline (day 0),
day 2, day 4, and day 9. One lL of 1% fluorescein (Sigma–Aldrich)
was applied to the inferior-lateral conjunctival sac of the mice, and
corneal fluorescein staining was examined with a slit-lamp biomicro-
scope under cobalt blue light 3 minutes later. Punctate staining was
evaluated in a masked fashion using the National Eye Institute
grading system, giving a score of 0 to 3 to each of the five areas of
the cornea.21
Systemic Administration of TLR4 Inhibitor
Eritoran tetrasodium (1.1 mg) and vehicle were gifted from Eisai
Research Institute (Andover, MA) and reconstituted in endotoxin-free
water (Sigma–Aldrich, Monticello, IA). Mice received either 50 lL of
Eritoran (5 mg/kg dissolved in vehicle) or vehicle once per day via
tail vein injection beginning 1 day prior to dry eye induction.17 Mice
were euthanized on day 7 or day 9 for cellular and molecular studies.
Real-Time Polymerase Chain Reaction
Total RNA was extracted from corneal tissue or bone marrow–derived
dendritic cells (BMDCs) using a commercial reagent (TRIzol; Invitrogen,
Carlsbad, CA) and an RNA purification kit (RNeasy Micro Kit; Qiagen,
Germantown, MD). First-strand cDNA was synthesized with random
hexamers using reverse transcriptase (SuperScript III; Invitrogen), and
quantitative real-time polymerase chain reaction (PCR) was performed
using predesigned primers (Taqman PCR Mastermix and FAM dye-labeled
primers; Applied Biosystems, Foster City, CA) for IL-1b
(Mm00434228_m1), IL-6 (Mm00446190_m1), TNF (Mm99999068_m1),
CCL2 (Mm00439620_m1), TLR4 (Mm00445273_m1), and glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Mm99999915_g1). The GAPDH
gene was used as the endogenous reference for each reaction. The results
were analyzed by the comparative threshold cycle (CT) method with
commercial analysis software (LightCycler, version 3; Roche Diagnostics
Corp., Indianapolis, IN) and the relative expression level of each sample
was expressed as fold change from wild-type DED or untreated DED
group.
Western Blot Assay
Ten corneal epithelial cell sheets were isolated from each group and
lysed in extraction buffer (10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 50
mM NaCl, 50 mM NaF, 1% Triton X-100, 20 lg/mL aprotinin, 2 mM
Na3VO4, and 1 mM phenylmethylsulfonyl fluoride) by homogeniza-
tion. Lysates were centrifuged for 10 minutes at 13,000g and 48C.
Total protein (100 lg) in each group was separated by 8% SDS-PAGE,
transferred to polyvinylidene difluoride membranes, and subjected to
Western blot analysis using TLR4 antibody (eBioscience Inc., San
Diego, CA). Signal intensity was determined by densitometry
(Quantity One; Bio-Rad, Hercules, CA) and normalized to the amount
of RasGAP, as an internal control, in each sample.
Analysis of Cellular Infiltration by
Immunohistochemical Staining
For whole-mount corneal staining of CD11bþ cells, corneas harvested
on day 9 were fixed in acetone for 15 minutes and incubated with
anti-FcR CD16/CD32 antibody (BD Pharmingen, San Diego, CA) for
45 minutes to block nonspecific staining. Corneas were immuno-
stained with primary or isotype antibody overnight and mounted
using a commercial mounting medium with DAPI (4,6 diamidino-2-
phenylindole; VectaShield; Vector Laboratories, Burlingame, CA), as
previously described.20 The following primary antibodies were used
for immunohistochemical staining: fluorescein isothiocyanate (FITC)–
conjugated rat anti–mouse CD11b (1:100; monocyte/macrophage
marker; BD Pharmingen) and FITC-conjugated rat IgG2bk (isotype
control; BD Pharmingen). Flat-mount corneas were examined with a
confocal microscope (Leica TCS–SP5; Leica Microsystems, Wetzlar,
Germany) at 3400 magnification and Z-stack images were taken
through the whole thickness of the corneal stroma. FITC-CD11bþ
cells in corneal stroma were counted in five to six areas in the
periphery (0.5-lm area from the limbus) and two areas in the center
of each cornea in a masked fashion using Z-stack images. The mean
number of cells was obtained by averaging the cell number in each
area examined.
Single Cell Isolation from the Cornea and Draining
Lymph Nodes
Excised corneas were incubated with 20 mM EDTA at 378C to separate
the epithelial and stromal layers, and these tissues were subsequently
digested in 2 mg/mL collagenase D (Roche Diagnostic Corp.) and 0.5
mg/mL DNase (Roche Diagnostic Corp.) for 2 hours at 378C. The
suspension was filtered through a 70-lm cell strainer (BD Falcon;
Becton-Dickinson, Franklin Lakes, NJ). Single-cell suspensions from
draining LNs were prepared with a 70-lm cell strainer. Trypan blue
exclusion assay confirmed cell viability.
Flow Cytometric Analysis
Cells were incubated with Fc blocking antibody in 0.5% BSA at 48C
for 30 minutes. Cells were then immunostained with the following
antibodies: FITC-conjugated anti-CD11b, Alexa Fluor 647–conjugated
anti-CD11c, allophycocyanin (APC)-Cy7-conjugated anti-I-Ab, APC-
conjugated anti-CD45, or PE-conjugated anti-TLR4 (UT41; eBioscience
Inc.). Isotype control was stained with the appropriately matched
antibodies (eBioscience Inc.). For intracellular staining of TLR4,
either a cell fixation/permeabilization kit (eBioscience Inc.) or 0.5%
Tween-20 was used. Cells were fixed with IC fixation buffer and then
incubated with permeabilization buffer and stained with PE-
conjugated anti-TLR4 antibody, per the manufacturer’s recommenda-
tions. Stained cells were analyzed with a flow cytometer (LSRII;
Becton-Dickinson) and a commercial program (Summit v4.3; Dako
Colorado, Inc., Fort Collins, CO).
Immunohistochemical Staining of TLR4-
Expressing Corneal Epithelial Cells
Corneal epithelial cell suspensions were immunostained with Alexa
Fluor 488–conjugated anti-TLR4 (UT41; eBioscience Inc.) for 2 hours
in 0.5% BSA at room temperature. Isotype control was stained with
Alexa Fluor 488–conjugated anti-mouse IgG1 antibody (eBioscience
Inc.). After washing these cells, epithelial cells were incubated with
plasma membrane stains (CellMask; Invitrogen) for 5 minutes at 378C
in RPMI media (Invitrogen-Gibco), according to the manufacturer’s
recommendations. FITC-TLR4 positive cells in corneal epithelial cells
were counted in six areas per each group under 3400 magnification
in a masked fashion. For intracellular staining of TLR4, the cell
fixation/permeabilization kit (eBioscience Inc.) was used as described
earlier.
In Vitro Stimulation of Bone Marrow–Derived
Dendritic Cells with Corneal Tissue
Bone marrow–derived dendritic cells (BMDCs) were generated using
a previously described method.22 In brief, femurs and tibias were
collected from freshly euthanized mice, flushed, and the resultant
cells were seeded at 1 3 106/mL in RPMI 1640 (BioWitthaker,
Walkersville, MD) supplemented with 10% fetal bovine serum
(Gemini Bio-products, West Sacramento, CA), 1% penicillin/strepto-
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mycin (Cambrex, East Rutherford, NJ), and 20 ng/mL mouse
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Biole-
gend, San Diego, CA) at 378C with 5% carbon dioxide. The medium
was exchanged with 10 mL medium containing 20 ng/mL GM-CSF on
day 4. Loosely adherent cells were harvested on day 7 after being
thoroughly washed with sterile PBS.
BMDCs (5 3 105 cells) were seeded on the bottom surface of a
24-well plate with either 100 ng/mL vehicle or Eritoran.13 Corneal
epithelium and stroma harvested from na¨ıve and dry eye–induced
mice were homogenized in 500 lL of sterile fresh culture medium.
Supernatants were centrifuged to remove undissolved particles and
added to the top of a tissue-culture insert with 1.0 lm pores
(Transwell; BD Falcon, Franklin Lakes, NJ). After BMDC pretreatment
with Eritoran or vehicle for 1 hour, BMDCs were incubated with
homogenized corneal tissue for 18 hours after which they were
collected in TRIzol for real-time PCR analysis.
Statistical Analyses
Data are expressed as the mean 6 SEM of at least three trials. The
significance of the difference between groups was analyzed with the
two-tailed Student’s t-test using commercial analytical software
(Prism, version 5.0; GraphPad, San Diego, CA). P < 0.05 was
considered statistically significant.
RESULTS
DED Increases TLR4 Expression on Corneal
Epithelial and Stromal Cells
The first experiment aimed to elucidate whether TLR4
expression on the cell surface of corneal epithelial and stromal
cells (including CD45 negative and positive cells) is modified in
DED. Corneal epithelial and stromal cells from dry eye–
induced or na¨ıve corneas were stained with anti-CD45 and anti-
TLR4 antibody. Dry eye induction significantly increased the
frequency of TLR4 expression on CD45 negative epithelial cells
(P ¼ 0.0039, Fig. 1A) and increased the mean fluorescence
intensity (MFI) of TLR4 expression on CD45 stromal cells
(8.05 6 2.17 in na¨ıve vs. 15.5 6 4.44 in DED, P ¼ 0.048, Fig.
1B) and CD45þ stromal cells (23.07 6 7.09 in na¨ıve vs. 43.23
6 12.24 in DED, P ¼ 0.034, Fig. 1C).
DED Causes Corneal Epithelial Cells to Translocate
Cytoplasmic TLR4 to the Cell Surface
Previous studies have reported that human corneal epithelial
cells express TLR4 protein intracellularly, but not on the cell
surface.12 In our study, extracellular and intracellular analysis
FIGURE 1. Expression of TLR4 in DED corneas. Representative histograms demonstrating increased cell surface expression of TLR4 in dry eye
corneas (red) as compared with normal corneas (black). After gating on CD45þ cells, flow cytometric analysis demonstrated that DED significantly
increased the cell surface expression of TLR4 on corneal epithelial cells (CD45) and stromal cells (CD45þ and CD45) as compared with the cells
of normal corneas: (A) corneal epithelial cells (CD45); (B) corneal stromal cells (CD45); (C) corneal stromal cells (CD45þ). Data are presented as
the mean 6 SEM of three experiments utilizing six corneas per group (*P < 0.05; **P < 0.01).
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of TLR4 with flow cytometry revealed that most TLR4 was
primarily located intracellularly in epithelial cells of the
normal cornea (data not shown), consistent with a previous
report involving human corneal epithelial cells.12 Interesting-
ly, DED increased the expression of TLR4 mRNA in the stroma
(P ¼ 0.035) after 7 days of dry eye induction, but not in the
epithelium. Furthermore, DED led to a significant increase in
the cell surface expression of TLR4 by corneal epithelial cells
as compared with those in the normal cornea as measured by
flow cytometry and immunohistochemical examination (P ¼
0.0003, Fig. 2A); however, there was no increase in either the
mRNA or protein levels of TLR4 in dry eye corneal epithelium
(Figs. 2B, 2C), suggesting that TLR4 is located intracellularly
in normal corneal epithelial cells and DED induces the
translocation of cytoplasmic TLR4 to the epithelial cell
surface.
FIGURE 2. Translocation of cytoplasmic TLR4 in DED corneal epithelial cells. (A) Immunohistochemical staining of cell surface and cytoplasmic
TLR4 on corneal epithelial cells from na¨ıve and DED-induced corneas with commercial-conjugated (Alexa Fluor 488) anti-TLR4 (green), commercial
plasma membrane (CellMask, dark red), and DAPI nuclear staining (blue). Representative confocal images depicting increased epithelial cell surface
expression of TLR4 in DED corneas as compared with na¨ıve corneas. FITC-TLR4 positive cells in corneal epithelial cells were counted at two areas
per slide for each group (two mice per group) under3400 magnification. Data are presented as the mean 6 SEM of three independent experiments
for a total of six mice per group. (B) Real-time PCR analysis revealed that TLR4 mRNA expression was increased in the stroma, but not epithelium, of
DED corneas on day 7. Data are presented as the mean 6 SEM of three experiments with three mice per group. (C) Western blot analysis
demonstrating that DED did not increase the expression of TLR4 protein relative to RasGAP, as an internal control, in the epithelium of DED corneas
as compared with na¨ıve corneas (*P < 0.05; **P < 0.01).
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Systemic TLR4 Inhibition Attenuates Dry Eye–
Induced Corneal Inflammation
To explore the function of TLR4 in the immunopathogenesis of
murine DED, we evaluated DED severity in mice treated with
systemic TLR4 inhibitor. TLR4 inhibitor was injected intrave-
nously every day beginning 1 day prior to dry eye induction.
TLR4 inhibitor–treated mice displayed significantly lower CFS
at day 4 (P¼0.029 vs. untreated; P¼0.012 vs. vehicle) and day
9 (P ¼ 0.0039 vs. untreated; P ¼ 0.0025 vs. vehicle, Fig. 3A),
and reduced expression of TNF (P¼0.0020 vs. vehicle) in DED
corneal epithelium and IL-1b (P¼ 0.027 vs. vehicle), IL-6 (P¼
0.0291 vs. vehicle), TNF (P ¼ 0.001 vs. untreated; P ¼ 0.0501
vs. vehicle), and CCL2 (P¼0.0150 vs. untreated; P¼0.1019 vs.
vehicle) in DED corneal stroma as compared with untreated
and/or vehicle-treated mice at day 9 (Fig. 3B).
Additionally, blockade of TLR4 in wild-type DED mice
significantly reduced the corneal infiltration of CD11bþ cells (P
¼ 0.0470 vs. untreated, P ¼ 0.0275 vs. vehicle in the central
cornea; P¼ 0.0178 vs. untreated, P¼ 0.0039 vs. vehicle in the
peripheral cornea; Fig. 4A) and the frequencies of MHC-
IIhighCD11bþ cells and MHC-IIhighCD11cþ cells in the draining
lymph nodes as compared with untreated and vehicle-treated
DED controls (Fig. 4B).
DED Induces Corneal Expression of Endogenous
TLR4 Ligands
To provide evidence that an endogenous TLR4 ligand is
involved in the inflammatory response to DED, we evaluated
the activation of BMDCs following coculture with homoge-
nized corneal tissues exposed to either vehicle or TLR4
inhibitor. Proinflammatory cytokine expression by DCs is an
important indicator of DC activity23,24 and our data for mRNA
expressions of these cytokines on BMDC after coculture are
provided in Supplemental Figure S1 (see Supplementary
Material and Supplementary Fig. S1, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.12-9547/-/DCSupplemental).
BMDCs expressed significantly higher mRNA levels of IL-1b (P
¼ 0.0003 for the corneal stroma) and TNF (P ¼ 0.001 for the
corneal epithelium; P ¼ 0.024 for the corneal stroma) in
response to homogenized dry eye corneal tissue, as compared
with na¨ıve corneal tissue (Fig. 5).
DISCUSSION
Dry eye disease is a multifactorial, immune-mediated disorder
of the ocular surface. Numerous studies have demonstrated
FIGURE 3. Systemic TLR4 inhibition decreases corneal inflammation in DED. (A) Systemic TLR4 blockade decreased the severity of CFS as
compared with both the untreated and vehicle-treated groups on days 4 and 9 (n ¼ 4 mice/8 eyes per group). Representative data from three
independent repeats. (B) Real-time polymerase chain reactions revealed that intravenous treatment with TLR4 inhibitor significantly decreased the
mRNA expression of IL-1b, IL-6, TNF, and CCL2 (MCP-1) as compared with untreated and vehicle-treated mice on day 9 (n¼ 4 corneas per group).
Data are presented as the mean 6 SEM of three or four experiments (*P < 0.05; **P < 0.01; ***P < 0.001).
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FIGURE 4. Systemic TLR4 inhibition suppressed inflammatory cell activity in DED. (A) Representative confocal images showing CD11bþ cell
(grayscale) infiltration of the central cornea. Intravenous TLR4 inhibition significantly decreased the number of CD11bþ cells in the periphery and
center of dry eye corneas as compared with untreated and vehicle-treated corneas at day 9. Data are presented as the mean 6 SEM of three or four
repeated experiments, involving three to four corneas per group (*P < 0.05; **P < 0.01). (B) Representative flow data demonstrating that systemic
TLR4 inhibition decreased the number of mature MHC-IIhighCD11bþ and MHC-IIhighCD11cþ APCs in the draining lymph nodes of dry eye mice,
compared with untreated and vehicle-treated mice. Representative flow data from two trials with pooled cells from four mice per group.
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that DED increases the ocular surface expression of proin-
flammatory cytokines such as IL-1b, IL-6, and TNF.21,25 These
cytokines activate resident APCs and promote the corneal
infiltration of additional CD11bþ cells.26,27 Activated APCs
subsequently stimulate an adaptive immune response, as
evidenced by the proliferation of CD4þ T cells in the draining
lymphatics.1,28 Furthermore, APCs prime pathogenic ocular
surface-specific CD4þ T cells (e.g., T helper 17 cells),
supporting the theory that DED has an autoimmune compo-
nent.28 Autoreactive CD4þ T cells are recruited to the ocular
surface by chemokines such as CCL2, CCL5, and CXCL9-11,
leading to immune-mediated ocular surface damage.7,25
TLR4 ligation results in the production of proinflammatory
cytokines such as IL-1b, IL-6, and TNF that promote the
activation of leukocytes and lymphocytes.10,29 TLR4 signaling
is important for the activation of APC- and T-cell–mediated
immunoinflammatory responses.15,16,30 The ligation of TLR4
on immature dendritic cells (DCs) leads to the downregulation
of CCR6 and upregulation of CCR7, thereby enhancing the
migration of DCs to draining lymph nodes.31,32 TLR4 signaling
is unique in that it involves the MyD88-dependent and -
independent pathways that increase the intensity and diversity
of responses to LPS.13,33
There is some controversy regarding the expression of
TLR4 by corneal epithelial cells. Song et al.34 have reported
that human corneal epithelial cells (HCEs) express TLR4 and
secrete proinflammatory mediators in response to stimulation
with LPS. However, Ueta et al.12 have reported that HCEs
express TLR2 and TLR4 only at the intracellular level, and the
intracellular transfer of LPS in vitro does not elicit an
inflammatory response. This unresponsiveness may have been
caused by deficient expression of LPS cofactors such as MD-2,
LBP, or CD14.15,33,35,36 MD-2–deficient mice do not experience
LPS-mediated endotoxic shock, a featured they share with
TLR4-deficient mice.37
In the present study, we found that TLR4 proteins are
primarily expressed intracellularly in normal murine corneal
epithelial cells, consistent with previous reports involving
HCEs.12 DED induction increased the cell surface expression of
TLR4 on corneal epithelial cells and stromal cells. Interestingly,
these increases occurred without corresponding increases in
the expression of TLR4 mRNA or protein. These findings
suggest that the cell surface expression of TLR4 increases
through the translocation of cytoplasmic TLR4. Previous
studies have shown that proinflammatory cytokines such as
TNF, IFN-c, and IL-17 can increase the expression of TLR4, MD-
2, and LPS-dependent cytokines by synovial tissue and
intestinal epithelial cells38,39; however, Ueta et al.12 have
reported that the stimulation of HCEs with IL-1b or TNF did not
increase the expression of cell surface TLR2 or TLR4.
Furthermore, oxidative stress causes the translocation of
TLR4 in alveolar macrophages, thereby permitting the aug-
mentation of LPS responsiveness.40 Based on the results of the
present experiment, we conclude that TLR4 expression can be
upregulated by extrinsic factors such as DED-associated
inflammation. Further investigation will be necessary to
identify which factors specifically induce the corneal epithelial
and stromal cell surface expression of TLR4 in response to
DED.
Systemic TLR4 blockade decreased the severity of DED as
compared with both untreated and vehicle-treated mice.
Previous studies have demonstrated that TLR4 deficiency
diminishes immunoinflammatory responses to nonocular
injury, as well as the severity of autoimmune diseases.41–45
TLR4-deficient mice express significantly lower levels of
proinflammatory mediators including TNF, IL-6, CCL2, CCL5,
and CXCL10 in a model of retinal ischemia.43 Furthermore,
TLR4-deficient mice demonstrate decreased infiltration of
inflammatory cells, particularly Th17 cells, and reduced
production of IL-17 in a rheumatoid arthritis model.45 TLR4
inhibition also diminishes the production of chemokines such
as IL-8/CXCL8 and CCL2, and reduces the infiltration of
inflammatory cells into the cornea in response to LPS
stimulation.13,20
TLR4 is an important mediator of immune responsiveness
not only to LPS, but also a variety of endogenous ligands
including heat shock proteins, high-mobility group box 1, and
extracellular matrix degradation products.29,42,46,47 In the
present study, we found that constituents of homogenized
DED corneal tissue can activate BMDC, and this activation is
abolished by the selective inhibition of TLR4. Recent studies
have demonstrated that the degradation of extracellular matrix
components including fibronectin, hyaluronic acid, and
heparan sulfate generates endogenous bioactivators of TLR4.
MMP-9 activity is significantly increased in DED, and MMP-9 is
involved in the degradation of corneal epithelial tight junctions
and basement membrane proteins.8,29,47,48 Furthermore, en-
dogenous TLR4 ligand (e.g., S100 A8 and A9) levels are
increased in the tears of patients with DED, and S100A8/A9
levels have been correlated with clinical disease severity.49,50
Therefore, we propose that DED-associated ocular surface
inflammation leads to the generation of endogenous TLR4
FIGURE 5. Evidence of endogenous TLR4 ligand expression in DED. Expression of IL-1b, IL-6, and TNF mRNA by bone marrow–derived dendritic
cells (BMDCs) was assessed following coculture with supernatants from homogenized DED or na¨ıve corneas (n ¼ 8 corneas per well). Dry eye
corneal tissue upregulated the expression of proinflammatory cytokines by BMDCs more than normal corneal tissue. [In vitro BMDC activation by
unknown endogenous TLR4 ligands ¼ (mRNA expression of BMDC cocultured with corneal tissue and vehicle)  (mRNA expression of BMDC
cocultured with corneal tissue and TLR4 inhibitor)]. Data are presented as the mean 6 SEM of three experiments for a total of 24 corneas per group
(*P < 0.05; **P < 0.01; ***P < 0.001).
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bioactivators, although the identity of these ligands remains to
be determined.
Herein, we present evidence that systemic TLR4 blockade
ameliorates the clinical signs of DED in association with
reduced corneal expression of proinflammatory cytokines,
reduced ocular surface APC infiltration, and decreased
maturation of APCs that migrate to the draining lymph nodes.
Taken together, these findings suggest that TLR4 expression is
upregulated in DED and TLR4 contributes to the inflammatory
response to desiccating stress at the ocular surface.
References
1. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry
eye is due to resistance of Th17 to Treg suppression. J
Immunol. 2009;182:1247–1252.
2. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an
immune-mediated ocular surface disorder. Arch Ophthalmol.
2012;130:90–100.
3. Lemp MA, Baudouin C, Baum J, et al. The definition and
classification of dry eye disease: report of the Definition and
Classification Subcommittee of the International Dry Eye
WorkShop (2007). Ocul Surf. 2007;5:75–92.
4. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates
production of inflammatory cytokines and MMP-9 and
activates MAPK signaling pathways on the ocular surface.
Invest Ophthalmol Vis Sci. 2004;45:4293–4301.
5. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced
apoptosis in human corneal epithelial cells is mediated by
cytochrome c and MAPK pathways. Cornea. 2007;26:452–
460.
6. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell
subpopulations in Sjo¨gren’s and non-Sjo¨gren’s patients with
dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609–2614.
7. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1
chemokines and chemokine receptors on the ocular surface of
C57BL/6 mice: effects of desiccating stress. Invest Ophthal-
mol Vis Sci. 2007;48:2561–2569.
8. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and
activity of matrix metalloproteinase-9 on the ocular surface
increase in dysfunctional tear syndrome. Invest Ophthalmol
Vis Sci. 2009;50:3203–3209.
9. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the
Toll-like receptor signal adaptor protein MyD88 in acute
allograft rejection. J Clin Invest. 2003;111:1571–1578.
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev
Immunol. 2004;4:499–511.
11. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative
expression of Toll-like receptor 1–10 mRNA in cellular subsets
of human peripheral blood mononuclear cells and sensitivity
to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531–
4537.
12. Ueta M, Nochi T, Jang MH, et al. Intracellularly expressed
TLR2s and TLR4s contribution to an immunosilent environ-
ment at the ocular mucosal epithelium. J Immunol. 2004;173:
3337–3347.
13. Sun Y, Pearlman E. Inhibition of corneal inflammation by the
TLR4 antagonist Eritoran tetrasodium (E5564). Invest Oph-
thalmol Vis Sci. 2009;50:1247–1254.
14. Medzhitov R, Janeway C Jr. Innate immune recognition:
mechanisms and pathways. Immunol Rev. 2000;173:89–97.
15. Zhang J, Kumar A, Wheater M, Yu FS. Lack of MD-2 expression
in human corneal epithelial cells is an underlying mechanism
of lipopolysaccharide (LPS) unresponsiveness. Immunol Cell
Biol. 2009;87:141–148.
16. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev
Immunol. 2003;21:335–376.
17. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of Toll-like
receptor 4 with eritoran attenuates myocardial ischemia-
reperfusion injury. Circulation. 2006;114(suppl 1):1270–
1274.
18. Kerfoot SM, Long EM, Hickey MJ, et al. TLR4 contributes to
disease-inducing mechanisms resulting in central nervous
system autoimmune disease. J Immunol. 2004;173:7070–
7077.
19. Barabino S, Shen L, Chen L, et al. The controlled-environment
chamber: a new mouse model of dry eye. Invest Ophthalmol
Vis Sci. 2005;46:2766–2771.
20. Lee HS, Chauhan SK, Okanobo A, Nallasamy N, Dana R.
Therapeutic efficacy of topical Epigallocatechin gallate in
murine dry eye. Cornea. 2011;30:1465–1472.
21. Lemp MA. Report of the National Eye Institute/Industry
workshop on clinical trials in dry eyes. CLAO J. 1995;21:
221–232.
22. Schlereth S, Lee HS, Khandelwal P, Saban DR. Blocking CCR7
at the ocular surface impairs the pathogenic contribution of
dendritic cells in allergic conjunctivitis. Am J Pathol. 2012;
180:2351–2360.
23. Banchereau J, Steinman RM. Dendritic cells and the control of
immunity. Nature. 1998;392:245–252.
24. Jurewicz M, Takakura A, Augello A, et al. Ischemic injury
enhances dendritic cell immunogenicity via TLR4 and NF-
kappa B activation. J Immunol. 2010;184:2939–2948.
25. Goyal S, Chauhan SK, Zhang Q, et al. Amelioration of murine
dry eye disease by topical antagonist to chemokine receptor 2.
Arch Ophthalmol. 2009;127:882–887.
26. Ecoiffier T, El Annan J, Rashid S, Schaumberg D, Dana R.
Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease.
Arch Ophthalmol. 2008;126:1695–1699.
27. Goyal S, Chauhan SK, Dana R, et al. Evidence of corneal
lymphangiogenesis in dry eye disease: a potential link to
adaptive immunity? Arch Ophthalmol. 2010;128:819–824.
28. Schaumburg CS, Siemasko KF, de Paiva CS, et al. Ocular surface
APCs are necessary for autoreactive T cell-mediated experi-
mental autoimmune lacrimal keratoconjunctivitis. J Immunol.
2011;187:3653–3662.
29. Marshak-Rothstein A. Toll-like receptors in systemic autoim-
mune disease. Nat Rev Immunol. 2006;6:823–835.
30. Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of
MyD88 and TRIF is critical for maximal TLR4-induced
dendritic cell maturation. J Immunol. 2008;181:1849–1858.
31. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of
immature and mature dendritic cells by distinct chemokines
expressed in different anatomic sites. J Exp Med. 1998;188:
373–386.
32. Kumar A, Yu FS. Toll-like receptors and corneal innate
immunity. Curr Mol Med. 2006;6:327–337.
33. Gioannini TL, Teghanemt A, Zhang D, et al. Isolation of an
endotoxin-MD-2 complex that produces Toll-like receptor 4-
dependent cell activation at picomolar concentrations. Proc
Natl Acad Sci USA. 2004;101:4186–4191.
34. Song PI, Abraham TA, Park Y, et al. The expression of
functional LPS receptor proteins CD14 and toll-like receptor 4
in human corneal cells. Invest Ophthalmol Vis Sci. 2001;42:
2867–2877.
35. Blais DR, Vascotto SG, Griffith M, Altosaar I. LBP and CD14
secreted in tears by the lacrimal glands modulate the LPS
response of corneal epithelial cells. Invest Ophthalmol Vis Sci.
2005;46:4235–4244.
36. Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Kimoto
M. Lipopolysaccharide-binding protein-mediated Toll-like re-
ceptor 4 dimerization enables rapid signal transduction against
lipopolysaccharide stimulation on membrane-associated
CD14-expressing cells. Int Immunol. 2010;22:271–280.
IOVS, August 2012, Vol. 53, No. 9 Contribution of TLR4 to Corneal Inflammation in Experimental DED 5639
37. Jiang Q, Akashi S, Miyake K, Petty HR. Cutting edge:
lipopolysaccharide induces physical proximity between
CD14 and Toll-like receptor 4 (TLR4) prior to nuclear
translocation of NF-jB. J Immunol. 2000;165:3541–3544.
38. Lee JH, Cho ML, Kim JI, et al. Interleukin 17 (IL-17) increases
the expression of Toll-like receptor-2, 4, and 9 by increasing IL-
1beta and IL-6 production in autoimmune arthritis. J
Rheumatol. 2009;36:684–692.
39. Abreu MT, Arnold ET, Thomas LS, et al. TLR4 and MD-2 expression
is regulated by immune-mediated signals in human intestinal
epithelial cells. J Biol Chem. 2002;277:20431–20437.
40. Powers KA, Sza´szi K, Khadaroo RG, et al. Oxidative stress
generated by hemorrhagic shock recruits Toll-like receptor 4
to the plasma membrane in macrophages. J Exp Med. 2006;
203:1951–1961.
41. Li Y, Si R, Feng Y, et al. Myocardial ischemia activates an
injurious innate immune signaling via cardiac heat shock
protein 60 and Toll-like receptor 4. J Biol Chem. 2011;286:
31308–31319.
42. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates
kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:
2847–2859.
43. Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI,
Ivanov D. Toll-like receptor 4 contributes to retinal ischemia/
reperfusion injury. Mol Vis. 2010;16:1907–1912.
44. Summers SA, Hoi A, Steinmetz OM, et al. TLR9 and TLR4 are
required for the development of autoimmunity and lupus
nephritis in pristane nephropathy. J Autoimmun. 2010;35:
291–298.
45. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al. Stimula-
tion of TLR2 and TLR4 differentially skews the balance of T
cells in a mouse model of arthritis. J Clin Invest. 2008;118:
205–216.
46. Yun TJ, Harning EK, Giza K, et al. EC144, a synthetic inhibitor
of heat shock protein 90, blocks innate and adaptive immune
responses in models of inflammation and autoimmunity. J
Immunol. 2011;186:563–575.
47. Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional
signaling by Toll-like receptor 4. FASEB J. 2005;19:872–874.
48. Sorokin L. The impact of the extracellular matrix on
inflammation. Nat Rev Immunol. 2010;10:712–723.
49. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are
endogenous activators of Toll-like receptor 4, promoting
lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–
1049.
50. Zhou L, Beuerman RW, Chan CM, et al. Identification of tear
fluid biomarkers in dry eye syndrome using iTRAQ quantita-
tive proteomics. J Proteome Res. 2009;8:4889–4905.
5640 Lee et al. IOVS, August 2012, Vol. 53, No. 9
